Category Archives: Nano medicine

LOS ANGELES--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ: EYES) (the Company or Second Sight), a leading developer of implantable visual prostheses that are intended to create an artificial form of useful vision for blind individuals, today announced that the Company received notice from the National Institutes of Health (NIH) of the release of year four funding for its Early Feasibility Clinical Trial of a Visual Cortical Prosthesis (the Orion Trial), grant 5UH3NS103442. The NIH released $1.1 million of the $6.4 million planned five-year grant. The Company uses the funds primarily to pay UCLA and Baylor College of Medicine to conduct the Orion Trial. The funding supports continuation of this important research and testing of the Orion Visual Cortical Prosthesis.

About the Orion Visual Cortical Prosthesis System

Leveraging Second Sights 20 years of experience in neuromodulation for vision, the Orion Visual Cortical Prosthesis System (Orion) is an implanted cortical stimulation device intended to provide useful artificial vision to individuals who are blind due to a wide range of causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury. Orion is intended to convert images captured by a miniature video camera mounted on glasses into a series of small electrical pulses. The device is designed to bypass diseased or injured eye anatomy and to transmit these electrical pulses wirelessly to an array of electrodes implanted on the surface of the brains visual cortex, where it is intended to provide the perception of patterns of light. An early feasibility study of the Orion is currently underway at the Ronald Reagan UCLA Medical Center in Los Angeles and the Baylor College of Medicine in Houston. No peer-reviewed data is available yet for the Orion system.

About Second Sight Medical Products, Inc.

Second Sight Medical Products, Inc. (Nasdaq: EYES) develops implantable visual prostheses that are intended to deliver useful artificial vision to blind individuals. A recognized global leader in neuromodulation devices for blindness, the Company is committed to developing new technologies to treat the broadest population of sight-impaired individuals. The Companys headquarters are in Los Angeles, California. More information is available at secondsight.com. On February 4, 2022, Second Sight entered into a merger agreement with Nano Precision Medical, Inc. (NPM), and, following approval by shareholders of the Company, anticipates concluding the merger in August 2022.

Safe Harbor

This press release contains certain forward-looking statements within the meaning of the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: target, believe, expect, will, may, anticipate, estimate, would, positioned, future, intended and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Examples of forward-looking statements include, among others, statements made in this press release regarding the amount of NIH grant proceeds expected to be received. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on Second Sights current beliefs, expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause actual results and outcomes to differ materially from those indicated in the forward-looking statements include, among others, the following: (1) legal claims or proceedings relating to Second Sights termination of the Memorandum of Understanding with Pixium Vision and costs relating thereto; (2) changes in applicable laws or regulations; (3) the possibility that Second Sight may be adversely affected by other economic, business, and/or competitive factors; (4) the impact of COVID-19 on Second Sights business; (5) the possibility that shareholders of the Company may not approve the merger with NPM or that the merger may not be completed for any other reason; and (6) various other risks and uncertainties. Some of these risks and uncertainties may in the future be amplified by the COVID-19 outbreak, including subvariants thereof and there may be additional risks that Second Sight considers immaterial or which are unknown. A further list and description of risks and uncertainties can be found in Second Sights Annual Report on Form 10-K filed on March 29, 2022, and in the Companys Forms 10-K/A filed on May 2, 2022, S-4 filed on May 13, 2022, and 10-Q filed on May 16, 2022, and as thereafter amended. Any forward-looking statement made by us in this press release is based only on information currently available to Second Sight and speaks only as of the date on which it is made. Second Sight undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.

Additional Information and Where to Find It

This communication, among other things, relates to a proposed business combination of the Company and NPM. The Company filed the registration statement on Form S-4 with the Securities and Exchange Commission (the SEC), which included a document that serves as a prospectus and proxy statement of the Company. The SEC declared the registration statement effective on June 24, 2022, and the proxy statement/prospectus was first mailed to shareholders of the Company on or about June 29, 2022. The proxy statement/prospectus described above contains important information about the Company, NPM, proposed merger, and related matters. This communication is not a substitute for the proxy statement/prospectus described above. Investors and securityholders are urged to carefully read the proxy statement/prospectus and all other relevant documents filed by the Company with the SEC because they contain important information about the merger and related matters. All documents are available free of charge at the SECs website (www.sec.gov). You may also obtain these documents by contacting Companys Investor Relations department at investors@secondsight.com.

Participants of Solicitation

The Company and its respective directors and executive officers may be deemed to be participants in any solicitation of proxies in connection with the proposed merger. Information about the Companys directors and executive officers is available in the Companys Annual Report on Form 10-K, as amended, for the fiscal year ended December 31, 2021. Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, is contained in the proxy statement/prospectus and all other relevant materials filed with the SEC regarding the proposed merger when they become available. This document is available from the Company free of charge as described in the preceding paragraph.

Read more here:
Second Sight Medical Products Announces Year Four NIH Funding of its Orion Study - Business Wire

20-month program to provide students with critical skill set to meet evolving business demands

NEW YORK, July 18, 2022 /PRNewswire/ -- As part of a commitment to prepare the business leaders of tomorrow, Columbia Business School and Columbia University's School of Engineering and Applied Science will offer a new dual-degree program that pairs the foundational skill sets of business with those of engineering. Students in the 20-month program will receive two degrees: a Master of Business Administration and an Executive Master of Science in Engineering and Applied Science. The program will officially launch in September 2023 and interested students can beginapplying now.

Designed to meet the evolving needs of leaders in technology, product managers, entrepreneurs, and other roles associated with technology and business, the Dual MBA/Executive MS in Engineering and Applied Science curriculumwill cover core engineering, areas of "tough tech," and applied science foundations, as well as essential business courses in leadership, strategy, finance, economics, and marketing. Students will take courses with both Columbia Business School and Columbia Engineering faculty, spend a summer pursuing an entrepreneurial venture or interning at a technology company, and complete a capstone project.

"Today's business challenges are multidisciplinary, and their solutions often lean on technological innovations. Students need, on one hand, a broad exposure to and understanding of how technology and engineering breakthroughs are shaping our lives today and the world of tomorrow. And, on the other hand, they need a deep understanding of business and, importantly, how to manage and lead in this dynamic environment," said Columbia Business SchoolDean Costis Maglaras, the David and Lyn Silfen Professor of Business. "In this competitive marketplace, Columbia's new MBAxMS: Engineering & Applied Science equips students with both the management skills and the science and technology core that enables them to move seamlessly from the classroom to product development to large-scale innovation and ultimately help create and grow companies and drive change."

The MBAxMS: Engineering & Applied Science core curriculum will focus on the creative application of technology and will include a variety of new and existing courses, including Digital Disruption & Tech Transfer, Business Analytics, Human-Centered Design and Innovation, and more. Students will also choose from an extensive array of electives designed to stimulate innovation, strengthen analytical skills, and bolster critical knowledge for their specific entrepreneurial or enterprise path.

"Technology, data, and analytics are transforming every aspect of modern businesses, especially those prized by the ambitious and entrepreneurial students who come to Columbia University," said Columbia Engineering Dean Shih-Fu Chang, the Morris A. and Alma Schapiro Professor of Engineering. "We recognize how important it is to provide students with broad exposures to emerging technology breakthroughs, the comprehensive training of business leadership skills, the unique experience in applying the human-centric design approach to innovative products and solutions, and importantly the ability to apply these unique skills in confronting major challenges facing our society and business world today. We look forward to partnering with Columbia Business School to launch an unprecedented program that can give our students a major boost."

The dual degree program, which is based in New York City, provides students with unmatched access and opportunities to work with and learn from the world's leaders in business, technology, data, analytics, and more. This includes opportunities to learn from guest speakers, meet with in-house mentors, and pursue internship opportunities that extend beyond the summer months. With one of the largest tech and entrepreneurial ecosystems in the country, the NYC location provides a unique, one-of-a-kind experience for the Dual MBA/Executive MS in Engineering and Applied Science students and graduates.

To learn more about the program, please visit https://academics.gsb.columbia.edu/mbaxms.

About Columbia Business SchoolColumbia Business School is the only world-class, Ivy League business school that delivers a learning experience where academic excellence meets with real-time exposure to the pulse of global business. The thought leadership of the School's faculty and staff members, combined with the accomplishments of its distinguished alumni and position in the center of global business, means that the School's efforts have an immediate, measurable impact on the forces shaping business every day. To learn more about Columbia Business School's position at the very center of business, please visitwww.gsb.columbia.edu.

About Columbia Engineering Columbia Engineering, based in New York City, is one of the top engineering schools in the U.S. and one of the oldest in the nation. Also known as The Fu Foundation School of Engineering and Applied Science, the School expands knowledge and advances technology through the pioneering research of its more than 250 faculty, while educating undergraduate and graduate students in a collaborative environment to become leaders informed by a firm foundation in engineering. The School's faculty are at the center of the University's cross-disciplinary research, contributing to the Data Science Institute, Earth Institute, Zuckerman Mind Brain Behavior Institute, Precision Medicine Initiative, and the Columbia Nano Initiative. Guided by its strategic vision, "Columbia Engineering for Humanity," the School aims to translate ideas into innovations that foster a sustainable, healthy, secure, connected, and creative humanity. To learn more about Columbia Engineering, please visit engineering.columbia.edu.

Cision

View original content:https://www.prnewswire.com/news-releases/columbia-business-school-and-columbia-engineering-to-offer-new-dual-mbaexecutive-ms-in-engineering-and-applied-science-program-301588295.html

SOURCE Columbia Business School

Continue reading here:
Columbia Business School and Columbia Engineering to Offer New "Dual MBA/Executive MS in Engineering and Applied Science" Program - Yahoo...

The Internet of Nano Things Market was valued at USD 9.90 billion in 2019 and is expected to reach USD 36.17 billion by 2025, at a CAGR of 24.12% over the forecast period 2022 2031. The internet of nano things is very much similar to the internet of technology in which the devices that are interconnected with IoNT are miniaturized.

The development of nano-machines with communication capabilities and interconnection with micro- and macro-devices will empower IoNT, which is being increasingly seen as the next major innovation in technology. These devices have dimensions ranging from 1 nm to 100 nm, and are interconnected with classical networks leading to new networking paradigms.

The increased government spending in the aerospace and defence sector is expected to drive the IoNT market for the forecast period as IoNT recently has found major applications in the fields of Nano-drones that could be used for monitoring and carrying explosives sufficient enough that penetrates the targeted subject.

The world economic forum in 2016, released the list of top 10 emerging technologies in which nano-sensors and nanotechnology were ranked first. As the integration of the nanotechnology in various industries increases, it would increase the dependence on IoT as a platform for nanodevices which would boost the IoNT market positively.

However huge capital investment required for the development of nanotechnology is a factor that could hinder the growth of the IoNT market.

Scope of the Report

The Interconnection of nanoscale devices with existing communication networks and ultimately the Internet defines a new networking paradigm called Internet of Nano-Things. This report segments the market by Device (Nano Cameras, Nano Phones, Nanosensors, Nano Processors, Nano-Memory Cards, Nano Power Systems, Nano-Antennas, Nano Transceivers), End-user (Healthcare, Logistics, Media & Entertainment, Telecom & IT, Defense & Aerospace, Manufacturing, Energy & Power, Retail), and Geography.

Download PDF Sample Report [emailprotected] https://www.sdki.us/sample-request-80865

Key Market Trends

Healthcare Industry is Expected to Hold a Significant Share

The expectations of a better quality of life coupled with the aging population and the changing lifestyles have resulted in an increase in demand for more efficient and affordable and improved healthcare.

For instance, Cambridge University nanotech researchers collaborated with a US insurer and other corporate players to explore the commercial potential of an intelligent lavatory that captures massive amount of key data in users urine which could then be used for the timely and effective delivery of the personalized medicines.

The development of nanomedicine which uses properties of a material developed on a nanoscale offering the potential to cross natural barriers and access new sites of delivery. This nanometric size allows interaction with the DNA or small proteins at different levels in the blood or within organs, tissues, and cells.

With advancements in the fields of nanotechnology has allowed in the detection of diseases in very minute amounts or in the initial stages. For instance, in April 2019, a pair of NJIT inventors Bharath Babu Nunna and Eon Soo Lee has been instrumental in developing nanotechnology enhanced biochip to detect cancers, malaria and viral diseases such as pneumonia early in their progression with a pinprick blood test.

With increased spending on healthcare by emerging and developed economies is expected to boost the investment in the fields of IoNT which would influence the market positively.

North-America is Expected to Hold the Largest Share

Various harmful diseases are proving to be a tremendous challenge for modern medicine. This, coupled with growing consumer health awareness in the region, means for more advanced technology. Nano medicine was introduced in this industry to overcome this hurdle since it offers a number of potential ways to improve medical diagnosis & therapy, even in regenerating tissues and organs.

Nanomaterials have been instrumental in improving a bodys acceptance of transplants, artificial bone materials, and other implanted medical devices. For instance, in 2016, the US Department of Health and Human Services invested USD 500 million for the development of medical devices containing nanomaterials.

Access Free Sample Report With Graphs and [emailprotected] https://www.sdki.us/sample-request-80865

Various companies have been instrumental in developing devices that drastically helps the person to improve breathing especially for asthma and allergy sufferers. For instance, Molekuiles Air purifier that was developed by Dr. Goswami, the Director of the University of South Floridas Clean Energy Research Center uses brand new nanotechnology that is far superior to the HEPA air filters.

Competitive Landscape

The internet of nano things market is highly competitive and consists of several key players like Schneider Electric, IBM, Intel and many more. However, the market remains consolidated with many players trying to occupy the share. Their ability to continually innovate their products and services by investing significantly in research and development has allowed them to gain a competitive advantage over other players.

About Us

SDKI Incgoal is market scenarios in various countries such as Japan, China, the United States, Canada, the United Kingdom, and Germany. We also focus on providing reliable research insights to clients around the world, including growth indicators, challenges, trends and competitive environments, through a diverse network of research analysts and consultants. With SDKI gaining trust and a customer base in more than 30 countries, SDKI is even more focused on expanding its foothold in other pristine economies.

Contact Us

Lauren Brown

600 S Tyler StSuite 2100 #140AMARILLO, TX 79101Email:[emailprotected]

Go here to see the original:
Internet of Nano Things Market is Poised to Grow at a CAGR of 24.12% during the Forecast Period of 2022-2031 - Digital Journal

If the stakeholders play it right, we could see the birth of a new industry whose essential raw material is something that is dumped as waste eggshells.

In recent years, the scientific community has been discovering the usefulness of eggshells in making bioceramics materials used to repair bones and teeth. Eggshells, non-toxic and plentifully available at practically no cost, are rich in calcium carbonate, which can be converted into a variety of calcium phosphates, the basic building material of bones and teeth. Recent research by Prof TS Sampath Kumar of the Medical Materials Laboratory, Department of Metallurgical and Materials Engineering, Indian Institute of Technology, Madras, identifies several pathways for the use of eggshell-derived chemicals in medicine as bone fillers, dental fillers, cements and drug delivery systems.

This is of particular interest to India, home to the worlds third largest poultry sector, where 730 million birds lay about 120 billion eggs a year roughly, 600,000 tonnes of eggshells. Kumar calls it a gold mine.

His research, published in the Journal of the Indian Institute of Science, tried to find out why eggshells are so suited to be made into bioceramics. When a doctor injects a paste into a fractured bone, it is expected to bond with the bone environment and become a part of it. Basic chemistry tells us that any bonding involves the attraction of ions, which are atoms that have more electrons than protons (negatively charged) or fewer (positively charged). So, proper bonding calls for the presence of ions. Bones have tiny amounts of magnesium, strontium, silicon and sodium. Kumars research showed that eggshells, too, have these. In fact, without these, the birds couldnt have made the eggs in the first place.

Eggshells are made up of calcium carbonate (94 per cent), calcium phosphate (1 per cent) and other organic matter (4 per cent). Calcium phosphates (CaPs) have been known to be good bone substitutes. Among the various CaPs, hydroxyapatite (HA) and its variant, calcium-deficient hydroxyapatite (CDHA), are known to help bone healing and bone regeneration.

Kumars Medical Materials Laboratory is tucked away in a nondescript, tiled shed that once used to house electrical generators. It has none of the glitzy sophistication of a buzzing chemical research centre. But, as it turns out, the researchers here didnt need anything more than a ream of writing paper and a microwave oven.

Using the microwave oven, Kumar and his team (comprising K Madhumathi and R Jayasree) synthesised HA and CDHA from cleaned chicken eggshells. (Eggshells were heated to 900 degrees C for three hours to convert calcium carbonate into calcium oxide, which, in turn, becomes calcium hydroxide on exposure to air. Adding diammonium hydrogen phosphate to this yielded nano CDHA).

The process was novel it was indeed a sort of cooking, with eggshells and phosphoric acid. The team was also able to tune the CDHA to vary the ratio of calcium to phosphorous for application-specific compositions.

While CDHA is a sort of flagship product, the team came up with a bunch of other products too. For example, they heated HA to 1,100 degrees C, and came up with tricalcium phosphate (TCP). Heat HA to 1,400 degrees C, you get tetra-calcium phosphate (TTCP), an excellent material for making cement to fix broken bones.

Further, any material that is introduced into the skeletal system to fill gaps or build back bones or gum together broken bones should ideally be capable of conducting drugs to wherever they are required. For example, if there is a bone infection, the man-made material should be a good drug carrier. Kumar says eggshell-derived materials are good at this too. It is not difficult to synthesise calcium phosphate in nano form. Nano materials distribute drugs well. Calcium phosphate nanoparticles offer more reaction sites for drug binding due to their high surface-to-volume ratios compared with bulk form. The researchers found out that eggshell-derived nano CDHA, tuned to a calcium-to-phosphate ratio of 1.61, was best suited for delivery of antibiotics, while eggshell-derived TCP was best for ibuprofen loading.

Thus, the team was able to produce a phalanx of products from eggshells, such as HA, CDHA (with variable calcium-to-phosphate ratios), carbonated apatite, amorphous calcium phosphate, TCP and TTCP, to suit specific medical applications. Kumar stressed that many more products could be derived from eggshells any calcium-based product. For example, carbonated apatite, a good cancer fighter, can be produced from eggshells.

It is pertinent to note that calcium phosphates have always been used for bioceramics. Whats new is that it can be made from eggshells. Kumar notes that people generally keep away from natural raw materials because they are non-homogenous. For instance, different eggshells from different parts of the country could have varying properties. The solution is to procure eggshells from a single source. On the other hand, eggshell-based bioceramics are better than synthetic bioceramics because they contain ions of magnesium, strontium, silicon and sodium. The various ions present in eggshell can not only play a key role in bone regeneration but also influence the binding of therapeutic molecules like proteins and drugs, Kumar says.

He says that the research is at a technology readiness level of 4 (TRL-4), which means it is ripe for the industry to scale it up. Further, the use of eggshells is still under-explored there would be many more specific applications. For example, 3D bioprinting with eggshell-derived biomaterials could lead to the fabrication of more functional tissues and organs.

One should also not forget the role of this eggshell-derived bioceramics in the circular economy. Indiscriminate disposal of eggshells leads to microbial contamination, a harm that we hardly take notice of. A push from the government towards collection of eggshells would be a big help, Kumar says.

Published onJuly 10, 2022

Link:
Eggshell and bioceramics: Break an egg to fix a tooth or two - BusinessLine

A reliable Nanomedicine in Central Nervous System Injury and Repair Market report has been organized with the contributions from a group of specialists in view of definite market examination. This market report has bits of knowledge about market definition, orders, applications, and commitment. The business report additionally incorporates notable information, present market patterns, climate, mechanical advancement, impending advances, and the specialized advancement in the connected business. By considering heap of targets of the showcasing research, this report has been produced. A worldwide statistical surveying report displays significant item improvements and tracks late acquisitions, consolidations, and exploration in the business by the top market players.

At the point when a boundless market overview report is there in the image, organizations can accomplish definite market experiences with which acquiring commercial center plainly into the center turns out to be simple. This business report covers central participants methodologies that basically comprise of new item dispatches, extensions, arrangements, joint endeavors, organizations, acquisitions, and others that advance their impressions in the business. It additionally illuminates about the moving development and business approaches. With the top notch report, organizations can find out about how the market will act in the conjecture a long time with justifiable insights regarding market definition, orders, applications, and commitment.

The nanomedicine in central nervous system injury and repair market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to reach at an estimated value of USD 51,419.82 million by 2028 and grow at a CAGR of 9.91% in the above-mentioned forecast period. Increase in the prevalence of central nervous system diseases such as Parkinsons disease, senile dementia, Alzheimer disease, ocular diseases among others drives the nanomedicine in central nervous system injury and repair market.

Download Exclusive Sample Report (350 Pages PDF with All Related Graphs & Charts) @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-nanomedicine-in-central-nervous-system-injury-and-repair-market

Major Players:-

The major players covered in the nanomedicine in central nervous system injury and repair market report are Abbott, Ablynx N.V, California Life Sciences Association, CELGENE CORPORATION, Teva Pharmaceutical Industries Limited, GENERAL ELECTRIC COMPANY, Merck Sharp & Dohme Corp (a subsidiary of Merck & Co., Inc), Pfizer Inc, Nanosphere Inc, Johnson & Johnson Private Limited and BD among other domestic and global players.

Competitive Landscape and Nanomedicine in Central Nervous System Injury and Repair Market Share Analysis

The nanomedicine in central nervous system injury and repair market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies focus related to nanomedicine in central nervous system injury and repair market.

Nanomedicine is defined as the nanotechnology which is used for treating, diagnosing, preventing diseases and traumatic injury, and to control of human biological systems using engineered nanodevices and nanostructures at the molecular level. Nanomedicine uses nano-tools that are 1000 times smaller than a cell for treatment of single cell and is also used in polymer therapeutics, regenerative medicine and targeted drug delivery.

Rise in the awareness related to nanomedicine applications is the vital factor escalating the market growth, also rise in thegovernmentfocus in terms of high funding for life science research and technological advancements in manufacturing process of nanomedicine, increase in the use of nanomedicine as probe or contrast agent in medical imaging techniques to extend the application of imaging and to improve the quality of images and rise in the healthcare expenditures are the major factors among others driving the nanomedicine in central nervous system injury and repair market. Moreover, rise in the technological advancements and modernization in the healthcare devices and rise in the risingresearch and developmentactivities in the healthcare sector will further create new opportunities for nanomedicine in central nervous system injury and repair market in the forecasted period of 2021-2028.

For More Insights Get FREE Detailed TOC @ https://www.databridgemarketresearch.com/toc/?dbmr=global-nanomedicine-in-central-nervous-system-injury-and-repair-market

However, high cost associated with nanomedicine based devices, rise in the stringent government regulations and increase in the risk of environment contamination due to release of toxic nanomaterials are the major factors among others which will obstruct the market growth, and will further challenge the growth of nanomedicine in central nervous system injury and repair market in the forecast period mentioned above.

This nanomedicine in central nervous system injury and repair market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the nanomedicine in central nervous system injury and repair market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Nanomedicine in Central Nervous System Injury and Repair Market Scope and Market Size

The nanomedicine in central nervous system injury and repair market is segmented on the basis of product and application. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

The nanomedicine in central nervous system injury and repair market is also segmented on the basis ofapplicationinto clinical oncology, infectious diseases, clinical cardiology, orthopedics and others.

Nanomedicine in Central Nervous System Injury and Repair Market Country Level Analysis

The nanomedicine in central nervous system injury and repair market is analysed and market size insights and trends are provided by product and application as referenced above.

The countries covered in the nanomedicine in central nervous system injury and repair market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the nanomedicine in central nervous system injury and repair market due to rise in the presence of technologically advanced healthcare infrastructure in this region. Asia-Pacific is the expected region in terms of growth in nanomedicine in central nervous system injury and repair market due to rise in the awareness about nanomedicine and high prevalence of chronic diseases in countries in the region.

The country section of the nanomedicine in central nervous system injury and repair market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure growth Installed base and New Technology Penetration

The nanomedicine in central nervous system injury and repair market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipments, installed base of different kind of products for nanomedicine in central nervous system injury and repair market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the nanomedicine in central nervous system injury and repair market. The data is available for historic period 2010 to 2019.

Read More @ https://www.databridgemarketresearch.com/reports/global-nanomedicine-in-central-nervous-system-injury-and-repair-market

Customization Available: Global Nanomedicine in Central Nervous System Injury and Repair Market

Data Bridge Market Researchis a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email @Corporatesales@databridgemarketresearch.com

Excerpt from:
Nanomedicine in Central Nervous System Injury and Repair Market Share, Regional Growth Analysis, Upcoming Trends, Growth Factors and Leading...

Carbon-based nanomaterials such as carbon nanotubes (CNTs), fullerenes, and graphene receive a great deal of attention today due to their unique physical properties. A new study explores the potential of hybrid nanostructures and introduces a new porous graphene CNT hybrid structure with remarkable thermal and mechanical properties.

Image Credit:Orange Deer studio/Shutterstock.com

The study shows how the remarkable characteristics of novel graphene CNT hybrid structures could be modified by slightly changing the inherent geometric arrangement of CNTs and graphene, plus various filler agents.

The ability to accurately control thermal conductivity and mechanical strength in the graphene CNT hybrid structures make them a potentially suitable candidate for various application areas, especially in advanced aerospace manufacturing where weight and strength are critical.

Carbon nanostructures and hybrids of multiple carbon nanostructures have been examined recently as potential candidates for numerous sensing, photovoltaic, antibacterial, energy storage, fuel cell, and environmental improvement applications.

The most prominent carbon-based nanostructures in the research appear to be CNTs, graphene, and fullerene. These structures exhibit unique thermal, mechanical, electronic, and biological properties due to their extremely small size.

Structures that measure in the sub-nanometer range behave according to the peculiar laws of quantum physics, and so they can be used to exploit nonintuitive phenomena such as quantum tunneling, quantum superposition, and quantum entanglement.

CNTs are tubes made out of carbon and that measure only a few nanometers across in diameter. CNTs display notable electrical conductivity, and some are semiconductor materials.

CNTs also have great tensile strength and thermal conductivity due to their nanostructure, and the strength of covalent bonds formed between carbon atoms.

CNTs are potentially valuable materials for electronics, optics, and composite materials, where they may replace carbon fibers in the next few years. Nanotechnology and materials science also use CNTs in research.

Graphene is a carbon allotrope that is shaped into a single layer of carbon atoms arranged in a two-dimensional lattice structure composed of hexagonal shapes. Graphene was first isolated in a series of groundbreaking experiments byUniversity of Manchester, UK, scientists Andrew Geim and Konstantin Novoselov in 2004, earning them the Nobel Prize for Physics in 2010.

In the few decades since then, graphene has become a useful nanomaterial with exceptionally high tensile strength, transparency, and electrical conductivity leading to numerous and varied applications in electronics, sensing, and other advanced technologies.

A fullerene is another carbon allotrope that has been known for some time. Its molecule consists of carbon atoms that are connected by single and double bonds to form a mesh, which can be closed or partially closed. The mesh is fused with rings of five, six, or seven atoms.

Fullerene molecules can be hollow spheres, ellipsoids, tubes, or a number of other shapes and sizes. Graphene could be considered an extreme member of the fullerene family, although it is considered a member of its own material class.

As well as a great deal of research invested into understanding and characterizing these carbon nanostructures in isolation, scientists are also exploring the properties of hybrid nanostructures that combine two or more nanostructure elements into one material.

For example, foam materials have adjustable properties that make them suitable for practical applications like sandwich structure design, biocompatibility design, and high strength and low weight structure design.

Carbon-based nanofoams have been utilized in medicine as well, examining bone injuries as well as acting as the base for replacement bone tissue.

Carbon-based cellular structures are produced both with chemical vapor deposition (CVD) and solution processing. Spark plasma sintering (SPS) methods are also implemented for using graphene for biological and medical applications.

As a result, scientists have been looking at ways to make three-dimensional carbon foams structurally stable. Research suggests that stable junctions between different types of structures (CNTs, fullerene, and graphene) need to be formed for this material to be stable enough for extensive application.

New research from mechanical engineers at Turkeys Istanbul Technical University introduces a new hybrid nanostructure formed through chemical bonding.

The porous graphene CNT structures were made by organizing graphene around CNTs in nanoribbons. The different geometrical arrangement of graphene nanoribbon layers around CNTs (square, hexagon, and diamond patterns) led to different physical properties being observed in the material, suggesting that this geometric rearrangement could be used to fine-tune the new structure.

The study was published in the journal Physica E: Low-dimensional Systems and Nanostructures in 2022.

Researchers found that the structures with fullerenes inserted, for example, exhibited significant compressive stability and strength without sacrificing tensile strength. The geometric arrangement of carbon nanostructures also had a significant effect on their thermal properties.

Researchers said that these new hybrid nanostructures present important advantages, especially for the aerospace industry. Nanoarchitectures with these hybrid structures may also be utilized in hydrogen storage and nanoelectronics.

Belkin, A., A. Hubler, and A. Bezryadin (2015). Self-Assembled Wiggling Nano-Structures and the Principle of Maximum Entropy Production. Scientific Reports. doi.org/10.1038/srep08323

Degirmenci, U., and M. Kirca (2022). Carbon-based nano lattice hybrid structures: Mechanical and thermal properties. Physica E: Low-dimensional Systems and Nanostructures. doi.org/10.1016/j.physe.2022.115392

Geim, A.K. (2009). Graphene: Status and Prospects. Science. /doi.org/10.1126/science.1158877

Geim, A.K., and K.S. Novoselov (2007). The rise of graphene. Nature Materials. doi.org/10.1038/nmat1849

Monthioux, M., and V.L. Kuznetsov (2006). Who should be given the credit for the discovery of carbon nanotubes? Carbon. doi.org/10.1016/j.carbon.2006.03.019

Disclaimer: The views expressed here are those of the author expressed in their private capacity and do not necessarily represent the views of AZoM.com Limited T/A AZoNetwork the owner and operator of this website. This disclaimer forms part of the Terms and conditions of use of this website.

See the original post here:
Notable Thermal and Mechanical Properties of New Hybrid Nanostructures - AZoM

Key Companies Covered in theNanorobotics MarketResearch areBruker, JEOL, Thermo Fisher Scientific, Ginkgo Bioworks, Oxford Instruments, EV Group, Imina Technologies, Toronto Nano Instrumentation, Klocke Nanotechnik, Kleindiek Nanotechnikand other key market players.

Global Nanorobotics Market is valued approximately USD 5.63 billion in 2019 and is anticipated to grow with a healthy growth rate of more than 7.24% over the forecast period 2020-2027.

Nanorobotics is a type of walk-in clinic that provides ambulatory care in a dedicated medical facility outside of a conventional emergency room (ER). Also, the Nanorobotics is used for treating injuries and illness that need immediate care. The increasing investments in urgent care, increasing geriatric population and strategic development between hospitals and urgent care providers has led the adoption of Nanorobotics across the forecast period.

Request To Download Free Sample of This Strategic Report:https://www.quadintel.com/request-sample/nanorobotics-market-2/QI037

as per the Journal of Urgent Care Medicine in 2017, Hospital Corporation of America has expanded Nanorobotics in an effort to build patient access points in its 14 major markets. Also, the Corporation use a portion of its effort $2.9 billion capital budget in 2017 to increase urgent care locations from 72 to 120 by the year-end. However, high manufacturing costs impedes the growth of the market over the forecast period of 2020-2027. Also, with the increasing prevalence of injuries, the adoption & demand for Nanorobotics is likely to increase the market growth during the forecast period.

The regional analysis of globalNanorobotics marketis considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. Europe is the leading/significant region across the world in terms of market share owing to the growing geriatric population and promptness & affordability of urgent care services coupled with the well-established healthcare infrastructure. Whereas, Asia-Pacific is also anticipated to exhibit highest growth rate / CAGR over the forecast period 2020-2027. Factors such as rising disposable income, rising incidences of injuries and improving healthcare infrastructure would create lucrative growth prospects for the Nanorobotics market across Asia-Pacific region.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

Download Free Sample Report, SPECIAL OFFER (Avail an Up-to 30% discount on this report)https://www.quadintel.com/request-sample/nanorobotics-market-2/QI037

The detailed segments and sub-segment of the market are explained below:

By Type:NanomanipulatorBio-NanoroboticsMagnetically GuidedBacteria-Based

By Application:NanomedicineBiomedicalMechanicalOthers

By Region:North AmericaU.S.CanadaEuropeUKGermanyFranceSpainItalyROE

Asia PacificChinaIndiaJapanAustraliaSouth KoreaRoAPACLatin AmericaBrazilMexicoRest of the World

Furthermore, years considered for the study are as follows:

Historical year 2017, 2018Base year 2019Forecast period 2020 to 2027

Target Audience of the Global Nanorobotics Market in Market Study:

Key Consulting Companies & AdvisorsLarge, medium-sized, and small enterprisesVenture capitalistsValue-Added Resellers (VARs)Third-party knowledge providersInvestment bankersInvestors

Request full Report Description, TOC, Table of Figure, Chart, etc.@https://www.quadintel.com/request-sample/nanorobotics-market-2/QI037

Table of content

Market OverviewMarket Definition and ScopeMarket DynamicsMarket Industry AnalysisMarket, Regional AnalysisAnalysis of Leading CompaniesCompetitive IntelligenceResearch ProcessMarket Analysis and Forecast, By Product Types

What is the goal of the report?

The market report presents the estimated size of the Market at the end of the forecast period. The report also examines historical and current market sizes. During the forecast period, the report analysis the growth rate, market size, and market valuation. The report presents current trends in the industry and the future potential of the North America, Asia Pacific, Europe, Latin America, and the Middle East and Africa markets. The report offers a comprehensive view of the market based on geographic scope, market segmentation, and key player financial performance.

What is the key information extracted from the report?

Extensive information on factors estimated to affect the Market growth and market share during the forecast period is presented in the report.The report offers the present scenario and future growth prospects Market in various geographical regions.The competitive landscape analysis on the market as well as the qualitative and quantitative information is delivered.The SWOT analysis is conducted along with Porters Five Force analysis.The in-depth analysis provides an insight into the Market, underlining the growth rate and opportunities offered in the business.

Request Full Reporthttps://www.quadintel.com/request-sample/nanorobotics-market-2/QI037

About Quadintel:

We are the best market research reports provider in the industry. Quadintel believes in providing quality reports to clients to meet the top line and bottom line goals which will boost your market share in todays competitive environment. Quadintel is a one-stop solution for individuals, organizations, and industries that are looking for innovative market research reports.

Get in Touch with Us:

Quadintel:Email:sales@quadintel.comAddress: Office 500 N Michigan Ave, Suite 600, Chicago, Illinois 60611, UNITED STATESTel: +1 888 212 3539 (US TOLL FREE)Website:https://www.quadintel.com/

More here:
Nanorobotics Market 2022 Research Report Analysis from Perspective of Segmentation and Industry Growth 2030 Designer Women - Designer Women

Redding, California, July 07, 2022 (GLOBE NEWSWIRE) -- According to a new market research report, Artificial Intelligence in Medical Diagnostics Market By Component (Software, Services), Specialty (Radiology, Cardiology, Neurology, Obstetrics/Gynecology, Ophthalmology), Modality (MRI, CT, X-ray, Ultrasound), End User (Hospital, Diagnostic Center) - Global Forecast to 2029,' published by Meticulous Research, the AI in medical diagnostics market is expected to grow at a CAGR of 36.2% during the forecast period to reach $9.38 billion by 2029.

DownloadFree Sample Report Now @https://www.meticulousresearch.com/download-sample-report/cp_id=5312

AI in medical diagnostics consists of AI software and services that aid healthcare professionals in identifying the diagnosis of different diseases. AI-based software solutions can analyze the data from a diagnostic procedure and either help triage patients by flagging abnormal medical images or suggest the healthcare professional a suitable diagnosis. AI in medical diagnostics integrates deep learning, data insights, and algorithms to detect life-threatening and critical diseases. It automates the diagnosis process and reduces the workload on healthcare professionals.

The main factors driving the AI in medical diagnostics market are the growing need for the adoption of AI in medical diagnosis due to the high rate of errors in medical diagnosis, shortage of healthcare professionals, and increasing prevalence of chronic diseases. Furthermore, the high growth potential in emerging economies and the growing number of cross-industry partnerships & collaborations are expected to provide significant growth opportunities for this market.

However, the reluctance to adopt AI technologies due to a lack of trust is expected to restrain the growth of this market to a notable extent. In addition, factors such as regulatory barriers and privacy and security concerns regarding patient data are the major challenges to the growth of this market.

The Impact of COVID-19 on the Artificial Intelligence in Medical Diagnostics Market

The outbreak of the COVID-19 pandemic in 2020 was a global public health challenge. The number of cases was skyrocketing, and many countries had a huge burden on the health system. The COVID-19 disease mainly affects the lungs of the patients. Hence, cardiothoracic imaging in COVID-19 cases is a common diagnostic practice to identify the severity of the disease. The number of research studies using AI techniques to diagnose COVID-19 rapidly increased in 2020. Many studies were focused on describing the diagnosis of COVID-19 from chest CT images using AI technology. Several studies proved that AI models might be as accurate as experienced radiologists in diagnosing COVID-19.

Speak to our Analysts to Understand the Impact of COVID-19 on Your Business:https://www.meticulousresearch.com/speak-to-analyst/cp_id=5312

CT scans were identified as the key modality for diagnosing COVID-19 at the onset of the disease. Healthcare professionals identified the severity of the disease from features like shadows over the patients lungs. A single patient had approximately 300 CT images, which took a doctor a lot of time to analyze with the naked eye. Also, radiologists needed to compare with earlier scans, increasing pressure on the healthcare staff. In such situations, AI-based systems can analyze CT images within 20 seconds, with an accuracy rate above 90% (Source: Nature Biomedical Engineering Journal). In addition, UC San Diego Health (U.S.) engineered a new method to expedite the diagnosis of pneumonia, a condition associated with severe COVID-19. This early detection helps doctors quickly triage patients to appropriate levels of care even before the COVID-19 diagnosis is confirmed. In May 2020, Mount Sinai Health System (U.S.) implemented artificial intelligence to analyze COVID-19 patients for rapid diagnosis based on CT scans and patient data. Thus, the advantages offered by AI technology have increased its adoption in medical diagnostics during the pandemic.

The AI in medical diagnostics market is segmented based on component, specialty, modality, end user, and geography. The study also evaluates industry competitors and analyzes the market at the country level.

Based on component, in 2022, the software segment is estimated to account for the largest share of the AI in medical diagnostics market. The large market share of this segment is attributed to the high demand for AI-based software solutions to deliver a quick and accurate medical diagnosis, the growing number of new software approvals & launches, and the rising shortage of specialists.

Based on specialty, in 2022, the radiology segment is estimated to account for the largest share of the AI in medical diagnostics market. The large market share of this segment is attributed to the growing demand for AI in medical imaging, increasing chronic disorders, an increasing number of new software products for AI in radiology, and the increasing global shortage of radiologists. In addition, the benefits of AI for radiologists in terms of non-interpretive data, such as reducing noise in medical images, creating high-quality images from lower doses of radiation, enhancing magnetic resonance image quality, and automatically assessing image quality, also supports the growth of this segment.

Based on modality, in 2022, the CT-scan segment is estimated to account for the largest share of the overall AI in medical diagnostics market. The large market share of this segment is attributed to the advantages that AI-based solutions offer, such as improved operational efficiency, reduced noise in medical images, and reduced patient backlogs and wait times. Additionally, the increasing patient pool prescribed for CT scans and growing numbers of products specific for CT scans supports the growth of this segment.

Quick Buy Artificial Intelligence in Medical Diagnostics Market Research Report: https://www.meticulousresearch.com/Checkout/76337122

Based on end user, in 2022, the hospitals segment is estimated to account for the largest share of the AI in medical diagnostics market. The large share of this segment is attributed to the increasing number of patients undergoing diagnostics procedures in hospitals, the robust financial capabilities of large hospitals to acquire high-cost AI-based software & services, the growing shortage of physicians, and the outbreak of the COVID-19 pandemic.

Based on geography, in 2022, North America is estimated to account for the largest share of the AI in medical diagnostics market, followed by Europe and Asia-Pacific. Some of the major factors driving the growth of the North American AI in medical diagnostics market include technological developments, increasing number of new product approvals, a high adoption rate of AI in healthcare, the presence of key market players, and established IT infrastructure in the healthcare sector. However, Asia-Pacific is slated to register the highest growth rate in the AI in medical diagnostics market during the forecast period. The high market growth in Asia-Pacific is attributed to the high growth opportunity due to the increasing prevalence of various chronic & infectious diseases, the increasing number of AI-based startups, especially in China and India, increasing funding, and a large potential of AI in addressing the gap in the healthcare infrastructure in the region

The report also includes an extensive assessment of the component, specialty, modality, end user, and geography, and key strategic developments adopted by leading market participants in the industry over the past four years (20192022). In recent years, the AI in medical diagnostics market has witnessed numerous product launches, approvals, agreements, collaborations, partnerships, and acquisitions.

The key players profiled in this market study are Siemens Healthineers AG (Germany), GE Healthcare (U.S.), Aidoc Medical Ltd. (Israel), International Business Machines Corporation (U.S.), AliveCor, Inc. (U.S.), VUNO Inc. (South Korea), Digital Diagnostics Inc. (U.S.), NovaSignal Corp. (U.S.), Riverain Technologies (U.S.), NANO-X IMAGING LTD (Israel), Imagen Technologies (U.S.), Koninklijke Philips N.V. (Netherlands), Agfa-Gevaert Group (Belgium), HeartFlow, Inc. (U.S.), and Arterys Inc. (U.S.).

To gain more insights into the market with a detailed table of content and figures, click here:https://www.meticulousresearch.com/product/artificial-intelligence-in-medical-diagnostics-market-5312

Scope of the Report:

Artificial Intelligence in Medical Diagnostics Market, by Component

Artificial Intelligence in Medical Diagnostics Market, by Specialty

Artificial Intelligence in Medical Diagnostics Market, by Modality

Artificial Intelligence in Medical Diagnostics Market, by End User

Artificial Intelligence in Medical Diagnostics Market, by Geography

Request Free Customization of Report @https://www.meticulousresearch.com/request-customization/cp_id=5312

Related Reports:

Healthcare Artificial Intelligence Market by Product and Services (Software, Services), Technology (Machine Learning, NLP), Application (Medical Imaging, Precision Medicine, Patient Management), End User (Hospitals, Patients) - Global Forecast to 2027

https://www.meticulousresearch.com/product/healthcare-artificial-intelligence-market-4937

Medical Image Management Market by Product {PACS [Departmental (Radiology, Mammography, Cardiology), Enterprise], VNA [(On-premise, Hybrid), [Vendor (PACS, Independent Software, Infrastructure)], AICA, Universal Viewer} and End User Global Forecast to 2027

https://www.meticulousresearch.com/product/medical-image-management-market-4761

Precision Medicine Software Market by Deployment Mode (On-premise, Cloud-based), Application (Oncology, Pharmacogenomics, CNS), End User (Healthcare Providers, Research, Academia, Pharma, Biotech) - Global Forecast to 2028

https://www.meticulousresearch.com/product/precision-medicine-software-market-5011

About Meticulous Research

Meticulous Research was founded in 2010 and incorporated as Meticulous Market Research Pvt. Ltd. in 2013 as a private limited company under the Companies Act, 1956. Since its incorporation, the company has become the leading provider of premium market intelligence in North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.

The name of our company defines our services, strengths, and values. Since the inception, we have only thrived to research, analyze, and present the critical market data with great attention to details. With the meticulous primary and secondary research techniques, we have built strong capabilities in data collection, interpretation, and analysis of data including qualitative and quantitative research with the finest team of analysts. We design our meticulously analyzed intelligent and value-driven syndicate market research reports, custom studies, quick turnaround research, and consulting solutions to address business challenges of sustainable growth.

Contact:Mr.Khushal BombeMeticulous Market Research Inc.1267WillisSt,Ste200 Redding,California,96001, U.S.USA: +1-646-781-8004Europe : +44-203-868-8738APAC: +91 744-7780008Email-sales@meticulousresearch.comVisit Our Website:https://www.meticulousresearch.com/Connect with us on LinkedIn-https://www.linkedin.com/company/meticulous-researchContent Source: https://www.meticulousresearch.com/pressrelease/538/artificial-intelligence-in-medical-diagnostics-market-2029

Read more here:
Artificial Intelligence in Medical Diagnostics Market Worth $9.38 Billion by 2029 - Exclusive Report by Meticulous Research - GlobeNewswire

The two-compartment nanoparticles as seen with structured illumination microscopy. The green compartment contains the immune drug while the red compartment brings the tumor-killer. Credit: Ava Mauser and Nahal Habibi, Lahann Lab, University of Michigan.

A new nanomedicine that crosses the blood-brain barrier, engages the immune system and kills cancer cells may offer hope for treating the most aggressive form of brain cancer, glioblastoma.

With $2.38 million in funding from the National Institutes of Health, the medicine will soon be tested in mice at the University of Michigan.

Led by a nano-engineer and neuro-oncology researchers at U-M, the study is the first to test the two drugs together, packaged so that they can be delivered through the bloodstream rather than a hole in the skull. It builds on previous success eliminating cancer in seven out of eight mice by packaging just the immune drug in the protein that crosses the blood-brain barrier so that it could be delivered intravenously. The five-year survival rate for glioblastoma in humans is about 5%.

The standard of care for glioblastoma is surgery and radiation, and the median survival hasnt improved for several decades. A systemically delivered nanomedicine that can prolong survival and prevent recurrence is the dream, said Maria Castro, the R.C. Schneider Collegiate Professor of Neurosurgery and professor of cell and developmental biology.

Her team leads the mouse studies in collaboration with Pedro Lowenstein, the Richard C. Schneider Collegiate Professor of Neurosurgery and professor of cell and developmental biology.

As the team tests out the nanoparticles timed to release the immune drug followed by a tumor-killing drug, developed and produced by project lead Joerg Lahanns group, one of the key questions is how well the drugs cooperate.

Are they working much better than either drug alone? Thats what were hoping for. Or is it just a small improvementor are they actually competing with each other and making the treatment worse or increasing the side effects? said Lahann, the Wolfgang Pauli Collegiate Professor of Engineering and director of the U-M Biointerfaces Institute.

The advanced nanomedicines are delivered intravenously and combined with radiation therapy, as they would be in a future clinical trial.

To get the nanomedicine from the bloodstream to the brain, Lahanns team packages the drugs in a protein called human serum albumin, which is present in blood and can cross the blood-brain barrier. Once there, the drugs must wake up the immune system to prevent recurrence and death, which frequently follow conventional treatments like surgery, radiation and chemotherapy.

Tumors grow and regrow because cancer cells have ways of suppressing the immune system. The 2020 study and the new grant use a drug that blocks STAT3, a signaling molecule that cancer cells use to tell immune cells not to attack them. This gave the immune system of the mice the ability to identify the cancer cells as targets for destruction.

In a study just out in May, the team used a drug that blocks CXCR4, an immune receptor that receives orders to send killer T-cells away. Blocking CXCR4 helps keep T-cells in the brain, where they do their work of killing brain cancer cells. Three out of five mice survived long term, and all of those survivors cleared new tumors during the recurrence challenge.

While the new grant wont use this drug, the team is interested in a future study exploring whether two immune approaches together might be more effective.

Tumors have a lot of variation, so we need to attack them from many directions, Lowenstein said.

After initial testing of the new two-compartment nanomedicine in lab-grown cell cultures that mimic human tumors and their surroundings, the team will begin testing in mice as the next step toward clinical trials in humans. They will find out how much of the nanomedicine makes it into the brain, how well it fights the cancer, how well it leaves the body and what the side effects are like.

Previous studies suggest that the nanoparticles home in on tumor cells, infiltrating them more often than healthy cells, and one of the goals for this one is to better understand how that works. For nanomedicines to advance into clinical trials as experimental treatments for glioblastoma, we must understand the mechanisms by which they accumulate in tumor and other tissues, said Colin Greineder, U-M assistant professor of emergency medicine, who will lead studies of how the nanomedicine distributes in the body.

More:
$2.38M to test nano-engineered brain cancer treatment in mice - University of Michigan News

Amrita Hospitals announced on Thursday that its new 2,400-bed campus will soon be open to the public in Faridabad in August this year. During the press conference on Thursday, hospital management announced that the new Amrita Hospital is spread across 133 acres of land in Faridabad and it will be the biggest private sector hospital in India.

This would be the second large-scale Amrita Hospital in India after the iconic 1,200-bed Amrita Hospital in Kochi, Kerala, which was established 25 years ago by the Mata Amritanandamayi Math.

The new hospital is located at Sector 88, Faridabad and it will have a total built-up area of 1 crore sq. ft., including a 14-floor-high tower that will encompass the key medical facilities and patient areas. During the press conference, Swami Nijamritananda Puri, Head, Mata Amritanandamayi Math, Delhi announced that the 81 specialties at the hospital will include eight centers of excellence, such as oncology, cardiac sciences, neurosciences, gastro-sciences, renal sciences, bone diseases and trauma, transplants, and mother and child.

The hospital will become operational in stages, with 500 beds opening in August this year. In two years, this number will rise to 750 beds, and further to 1,000 beds in five years. When fully operational, the hospital will have a staff of 10,000 people, including over 800 doctors.

On how the new hospital has incorporated the aspects of pandemic-induced demands, Dr. Sanjeev K Singh, Medical Director, Amrita Hospital, Faridabad told Financial Express.com: We have learned a lot from the pandemic. The construction of the hospital began 5-6 years ago and the learnings from the pandemic also got incorporated along the way. For example, any patient who comes in an emergency gets facilitated in a 40-bed setup. In that set-up, we have a decontaminated area in which anyone who needs to shower will be sent there. We have four negative pressure rooms and if we have any suspected cases of covid or covid-like diseases we can send them to concerned specialists. The mechanism of shifting is also planned and implemented. In all critical care units, there are positive pressure isolation rooms.

The massive facility will also include 534 critical care beds which is the highest in India, the hospital management claims. The hospital campus will also include 64 modular operation theaters, most advanced imaging services, fully automated robotic laboratory, high-precision radiation oncology, most updated nuclear medicine, and state-of-the-art 9 cardiac and interventional cath lab for clinical services. Cutting-edge medical research will be a strong thrust area, with a dedicated research block spread across a 7-floor building totaling 3 lakh sq. ft with exclusive Grade A to D GMP lab with focus on identifying newer diagnostic markers, AI, ML, Bioinformatics etc.

Dr. Singh also told Financial Express.com that they want to integrate all aspects of medical science and bridge the gap between clinicians and scientists.

In Kochi, we have established tissue engineering, a nano-medicine-based cardiac stent, bone growth, and lots more. What we are looking at Faridabad campus is developing something new in stem-cell therapies. We want to create techniques like creating human cells on our own in our GMP labs as generally, we rely on international counterparts for such procedures. Recently, we conducted research in which we found that we can use patient pluripetin stem cells in tumours and it will destroy them. For us, oncology is the big thrust area but other areas will be a focus too. The intent of our research facility will be to make the high-end expensive equipment and treatments cost-effective for the common man. We want to integrate medicine, engineering, biotechnology, and other segments altogether, Dr. Singh told Financial Express.com.

Dr. Singh also said that they have already been awarded the Advanced ICMR Clinical Trial Unit and this will enable them to conduct their trials in the new facility.

Mata Amritanandamayi has allocated a certain amount of seed money to initiate research. On the basis of submitted proposals, things will materialise and start, he added.

Dr. Singh also told Financial Express.com that the new hospital will also be empaneled. There is a process of 3-6 months and then after medical facilities will be available under all panels like ECHS, CGHS and other TPAs, he added.

During the press conference, Dr Singh also informed that the hospital will be among the very few facilities in the country to conduct hand transplants, a specialty pioneered by Amrita Hospital in Kochi. We will also do transplants of liver, kidney, trachea, vocal cords, intestine, heart, lung, pancreas, skin, bone, face and bone marrow, he said.

Training of medical students and doctors will be a strong focus area. The hospital will have state-of-the-art robotics, haptic, surgical-medical simulation centre spread across 4 floors and 1.5 lakh sq. ft area, the biggest such learning & development facility for doctors in the country. The facility will also host a medical college and the countrys biggest allied health sciences campus, he stated.

Moreover, the management also informed that ultra-modern Amrita Hospital at Faridabad would be one of Indias largest green-building healthcare projects with a low carbon footprint. It is an end-to-end paperless facility, with zero waste discharge.

There is also a helipad on the campus for swift transport of patients and a 498-room guest house where attendants accompanying the patients can stay, they said.

See the rest here:
New Amrita Hospital is all set to open in Faridabad in August this year; 2,400-bed facility will become Indias biggest private hospital - The...